Down-regulation of the mitochondrial aspartate-glutamate carrier isoform 1 AGC1 inhibits proliferation and N-acetylaspartate synthesis in Neuro2A cells.

Emanuela Profilo, Luis Emiliano Peña-Altamira, Mariangela Corricelli, Alessandra Castegna, Alberto Danese, Gennaro Agrimi, Sabrina Petralla, Giulia Giannuzzi, Vito Porcelli, Luigi Sbano, Carlo Viscomi, Francesca Massenzio, Erika Mariana Palmieri, Carlotta Giorgi, Giuseppe Fiermonte, Marco Virgili, Luigi Palmieri, Massimo Zeviani, Paolo Pinton, Barbara Monti, Ferdinando Palmieri, Francesco Massimo Lasorsa

Journal: Biochimica et biophysica acta. Molecular basis of disease 2018;1863(6):1422-1435

PMID: 28235644

Abstract

The mitochondrial aspartate-glutamate carrier isoform 1 (AGC1) catalyzes a Ca-stimulated export of aspartate to the cytosol in exchange for glutamate, and is a key component of the malate-aspartate shuttle which transfers NADH reducing equivalents from the cytosol to mitochondria. By sustaining the complete glucose oxidation, AGC1 is thought to be important in providing energy for cells, in particular in the CNS and muscle where this protein is mainly expressed. Defects in the AGC1 gene cause AGC1 deficiency, an infantile encephalopathy with delayed myelination and reduced brain N-acetylaspartate (NAA) levels, the precursor of myelin synthesis in the CNS. Here, we show that undifferentiated Neuro2A cells with down-regulated AGC1 display a significant proliferation deficit associated with reduced mitochondrial respiration, and are unable to synthesize NAA properly. In the presence of high glutamine oxidation, cells with reduced AGC1 restore cell proliferation, although oxidative stress increases and NAA synthesis deficit persists. Our data suggest that the cellular energetic deficit due to AGC1 impairment is associated with inappropriate aspartate levels to support neuronal proliferation when glutamine is not used as metabolic substrate, and we propose that delayed myelination in AGC1 deficiency patients could be attributable, at least in part, to neuronal loss combined with lack of NAA synthesis occurring during the nervous system development.

Copyright © 2017 Elsevier B.V. All rights reserved.

Address: Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari 'Aldo Moro', Bari 70125, Italy.; Department of Pharmacy and BioTechnology, University of Bologna, Bologna 40126, Italy.; Department of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara 44121, Italy.; MRC-Mitochondrial Biology Unit, Cambridge, UK; Fondazione IRCCS Istituto Neurologico "C. Besta", Milan, Italy.; Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari 'Aldo Moro', Bari 70125, Italy; Institute of Biomembranes and Bioenergetics, Consiglio Nazionale delle Ricerche, Bari 70126, Italy.; Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari 'Aldo Moro', Bari 70125, Italy; Institute of Biomembranes and Bioenergetics, Consiglio Nazionale delle Ricerche, Bari 70126, Italy. Electronic address: [email protected].; Institute of Biomembranes and Bioenergetics, Consiglio Nazionale delle Ricerche, Bari 70126, Italy. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.